Claims for Patent: 6,960,352

Summary for Patent: 6,960,352

Title:	Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent
Abstract:	The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.
Inventor(s):	Noujaim; Antoine (Edmonton, CA), Person; Roland H. (Kelowna, CA), Stewart; Michael W. (St Albert, CA)
Assignee:	ViRexx Medical Corporation (Edmonton, CA)
Application Number:	10/241,717
Patent Claims:	1. A method for treating a vascularized tumor or hyperplastic tissue, comprising administering to a mammal at a pre-determined site at or near a vascularized tumor or hyperplastic tissue, a solid-phase agent comprising a binding agent capable of binding platelets, said binding agent being selected from the group consisting of mammalian von Willebrand Factor and recombinant von Willebrand Factor (VWF), and subsequently inducing a thrombus in vivo comprising: capturing platelets by binding the platelets to the platelet binding agent immobilized on or within the solid-phase agent, inducing activation of the platelets, and allowing a thrombus to form at said pre-determined site, thereby limiting the blood supply at said pre-determined site and treating said vascularized tumor or hyperplastic tissue. 2. The method of claim 1 wherein the solid-phase agent is a particle. 3. The method of claim 1 wherein the solid-phase agent is a coil. 4. The method of claim 1 wherein the solid-phase agent is a stent. 5. The method of claim 1 wherein the VWF is of human origin. 6. The method of claim 1, wherein the VWF is of porcine origin. 7. The method of claim 1 wherein the solid-phase agent includes a targeting moiety. 8. The method of claim 7 wherein the targeting moiety is directed to an antigen(s) on target vasculature. 9. The method of claim 1 wherein the solid-phase agent comprises biotin or avidin or derivatives thereof. 10. The method of claim 8 wherein the targeting moiety comprises biotin, peptides, human Fc fragments, a fusion protein, alone or in combination. 11. The method of claim 2 wherein the particle size is from about 8 microns to about 7000 microns. 12. The method of claim 2 wherein the particle size is from about 8 microns to about 150 microns. 13. The method of claim 2 wherein the particle size is from about 200 microns to about 1000 microns. 14. The method of claim 3 further comprising coating the coil with von Willebrand Factor. 15. The method of claim 4 further comprising coating the stent with von Willebrand Factor. 16. The binding agent of claim 1 wherein von Willebrand Factor is directly or indirectly bound to the solid-phase agent. 17. The method of claim 1 further comprising administering a platelet-binding modulator. 18. The method of claim 7 wherein the targeting moiety is a targeting moiety selected from the group consisting of an antibody or fragment thereof, a ligand, a receptor, a hormone, a lectin, a cadherin, and binding or fragments thereof. 19. A method of treating a vascularized tumor or hyperplastic tissue comprising administering to a pre-determined site at or near a vascularized tumor or hyperplastic tissue von Willebrand Factor bound to a solid support, allowing the von Willebrand Factor to capture end activate platelets, and allowing the activated platelets to form a thrombus. 20. A method for treating a vascularized tumor or hyperplastic tissue comprising coating von Willebrand Factor on macro-aggregated albumin to form immobilized von Willebrand Factor, delivering the immobilized von Willebrand Factor to a pre-selected site near or on the vascularized tumor or hyperplastic tissue, and allowing the immobilized von Willebrand Factor to capture and activate platelets, thereby producing a thrombus. 21. The method of claim 1 wherein administering comprises administering using a catheter, microcatheter, needle, syringe, by a surgical procedure, or by manual placement. 22. The method of claim 2 wherein administering comprises administering using a catheter, microcatheter, needle, syringe, or by a surgical procedure. 23. The method of claim 3 wherein administering comprises administering using a catheter, microcatheter, syringe, by a surgical procedure, or by manual placement. 24. The method of claim 4 wherein administering comprises administering using a catheter, microcatheter, syringe, by a surgical procedure, or by manual placement. 25. The method of claim 2 wherein the particle is formed of a material capable of retaining vWF. 26. The method of claim 25 wherein the material is selected from the group consisting of polyvinyl alcohol (PVA); polystyrene; polycarbonate; polylactide; polyglycolide; lactide-glycolide copolymers; polycaprolactone; lactide-caprolactone copolymers; polyhydroxybutyrate; polyalkylcyanoacrylates; polyanhydrides; polyorthoesters; albumin; collagen; gelatin; polysaccharides; dextrans; starches; methyl methacrylate; methacrylic acid; hydroxylalkyl acrylates; hydroxylalkyl methacrylates; methylene glycol dimethacrylate; acrylamide; bisacrylamide; cellulose-based polymers; ethylene glycol polymers and copolymers; oxyethylene and oxypropylene polymers; polyvinyl acetate; polyvinylpyrrolidone and polyvinylpyridine; magnetic particles; fluorescent particles; animal cells; plant cells; macro-aggregated and micro-aggregated albumin; denatured protein aggregates, and liposomes; any of the above used singly or in combination. 27. The method of claim 25 wherein the material is selected from the group consisting of polylactide; polyglycolide; and lactide-glycolide copolymers. 28. The method of claim 25 wherein the material is selected from the group consisting of polyvinyl alcohol (PVA); polystyrene; polycarbonate; polycaprolactone; lactide-caprolactone copolymers; polyhydroxybutyrate; polyalkylcyanoacrylates; polyanhydrides; and polyorthoesters. 29. The method of claim 25 wherein the material is selected from the group consisting of albumin; collagen; gelatin; polysaccharides; dextrans; and starches. 30. The method of claim 25 wherein the material is selected from the group consisting of methyl methacrylate; methacrylic acid; hydroxylalkyl acrylates; hydroxylalkyl methacrylates; and methylene glycol dimethacrylate. 31. The method of claim 25 wherein the material is selected from the group consisting of acrylamide; bisacrylamide; cellulose-based polymers; ethylene glycol polymers and copolymers; oxyethylene and oxypropylene polymers; polyvinyl acetate; polyvinylpyrrolidone and polyvinylpyridine. 32. The method of claim 25 wherein the material is selected from the group consisting of magnetic particles and fluorescent particles. 33. The method of claim 25 wherein the material is selected from the group consisting of animal cells and plant cells. 34. The method of claim 25 wherein the material is selected from the group consisting of macro-aggregated and micro-aggregated albumin; and denatured protein aggregates. 35. The method of claim 25 wherein the material is liposomes. 36. The method of claim 26 wherein the material is selected from the group consisting of polylactide; polyglycolide; lactide-glycolide copolymers; macro-aggregated and micro-aggregated albumin. 37. The method of claim 1 wherein the binding agent is bound on or in the solid phase agent. 38. The method of claim 37 wherein the binding agent is bound directly to the solid phase agent. 39. The method of claim 37 wherein the binding agent is bound directly to the solid phase agent using covalent or non-covalent binding. 40. The method of claim 37 wherein the binding agent is bound indirectly to the solid phase agent. 41. The method of claim 37 wherein the binding agent is bound indirectly to the solid phase agent using one or more spacers. 42. The method of claim 41 wherein the spacers are selected from one or more of the group consisting of peptide spacer arms, antibody spacers, antibody fragment spacers, fusion protein spacers and carbohydrate spacers. 43. The method of claim 42 wherein the antibody fragment spacer is an Fc portion of an antibody. 44. The method of claim 1 wherein the mammal and the source of mammalian von Willebrand Factor is autologous. 45. The method of claim 1 wherein the mammal and the source of mammalian von Willebrand Factor is heterologous. 46. The method of claim 44 wherein the mammal and the source of vWF is human. 47. The method of claim 44 wherein the mammal and the source of vWF is porcine. 48. The method of claim 45 wherein the mammal is human and the source of vWF is porcine. 49. A method for treating a vascularized tumor or hyperplastic tissue, comprising administering to a human at a pre-determined site at or near a vascularized tumor or hyperplastic tissue, a solid phase agent indirectly bound to a binding agent capable of binding platelets, said binding agent being selected from the group consisting of mammalian von Willebrand Factor and recombinant von Willebrand Factor, and subsequently inducing a thrombus in vivo comprising: capturing platelets by binding the platelets to the platelet binding agent immobilized on or within the solid phase agent; inducing activation of the platelets, and allowing a thrombus to form at said site, thereby limiting the blood supply at said pre-determined site and treating said vascularized tumor or hyperplastic tissue. 50. The method of claim 49 wherein the von Willebrand Factor is human or porcine. 51. The method of claim 49 wherein the binding agent is immobilized on or within the solid phase agent using an antibody or antibody fragment. 52. The method of claim 1 wherein at the site of a vascularized tumor or hyperplastic tissue comprises an organ or associated vasculature.

Details for Patent 6,960,352

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	December 08, 2015	6,960,352	2022-09-12